179 related articles for article (PubMed ID: 30530568)
21. A case of rare recessive oculopharyngeal muscular dystrophy (OPMD) coexisting with hereditary neuropathy with liability to pressure palsies (HNPP).
Marsh EA; Robinson DO
Clin Neurol Neurosurg; 2008 May; 110(5):525-8. PubMed ID: 18358598
[TBL] [Abstract][Full Text] [Related]
22. Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies.
Abu-Baker A; Rouleau GA
Biochim Biophys Acta; 2007 Feb; 1772(2):173-85. PubMed ID: 17110089
[TBL] [Abstract][Full Text] [Related]
23. Functional impact of an oculopharyngeal muscular dystrophy mutation in PABPN1.
García-Castañeda M; Vega AV; Rodríguez R; Montiel-Jaen MG; Cisneros B; Zarain-Herzberg A; Avila G
J Physiol; 2017 Jul; 595(13):4167-4187. PubMed ID: 28303574
[TBL] [Abstract][Full Text] [Related]
24. Clinical and genetic features of a large homogeneous cohort of oculopharyngeal muscular dystrophy patients from the Canary Islands.
Alonso-Pérez J; de León Hernández JC; Pérez-Pérez H; Mendoza-Grimón MD; Gutierrez-Martinez AJ; Hadjigeorgiou I; Montón-Álvarez F; González-Quereda L; Alonso-Jimenez A; Suárez-Calvet X; Díaz-Manera J
Eur J Neurol; 2022 May; 29(5):1488-1495. PubMed ID: 35112761
[TBL] [Abstract][Full Text] [Related]
25. [Preferential distal muscle involvement in case of oculopharyngeal muscular dystrophy with (GCG) 13 expansion].
Nakashima D; Nakajima H; Ishida S; Sugino M; Kimura F; Hanafusa T
Rinsho Shinkeigaku; 2003 Sep; 43(9):560-3. PubMed ID: 14727564
[TBL] [Abstract][Full Text] [Related]
26. Oculopharyngeal muscular dystrophy associated with dementia.
Mizoi Y; Yamamoto T; Minami N; Ohkuma A; Nonaka I; Nishino I; Tamura N; Amano T; Araki N
Intern Med; 2011; 50(20):2409-12. PubMed ID: 22001477
[TBL] [Abstract][Full Text] [Related]
27. Oculopharyngeal muscular dystrophy: phenotypic and genotypic characteristics of 9 Polish patients.
Nadaj-Pakleza A; Richard P; Lusakowska A; Gajewska J; Jamrozik Z; Kostera-Pruszczyk A; Kwieciński H; Kamińska A
Neurol Neurochir Pol; 2009; 43(2):113-20. PubMed ID: 19484687
[TBL] [Abstract][Full Text] [Related]
28. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy.
Davies JE; Sarkar S; Rubinsztein DC
Hum Mol Genet; 2006 Jan; 15(1):23-31. PubMed ID: 16311254
[TBL] [Abstract][Full Text] [Related]
29. Two cases of oculopharyngeal muscular dystrophy (OPMD) with the rare PABPN1 c.35G>C; p.Gly12Ala point mutation.
Robinson DO; Hilton-Jones D; Mansfield D; Hildebrand GD; Marks S; Mechan D; Ramsay J
Neuromuscul Disord; 2011 Nov; 21(11):809-11. PubMed ID: 21742497
[TBL] [Abstract][Full Text] [Related]
30. PABPN1 gene therapy for oculopharyngeal muscular dystrophy.
Malerba A; Klein P; Bachtarzi H; Jarmin SA; Cordova G; Ferry A; Strings V; Espinoza MP; Mamchaoui K; Blumen SC; St Guily JL; Mouly V; Graham M; Butler-Browne G; Suhy DA; Trollet C; Dickson G
Nat Commun; 2017 Mar; 8():14848. PubMed ID: 28361972
[TBL] [Abstract][Full Text] [Related]
31. Study of a Taiwanese family with oculopharyngeal muscular dystrophy.
Kuo HC; Chen CM; Lee-Chen GJ; Hu FJ; Chu CC; Liou CW; Huang CC
J Neurol Sci; 2009 Mar; 278(1-2):21-4. PubMed ID: 19101703
[TBL] [Abstract][Full Text] [Related]
32. Oculopharyngeal Muscular Dystrophy and Inherited Retinal Dystrophy in Bukhara Jews Due to Linked Mutations in the PABPN1 and NRL Genes.
Braverman I; Blumen SC; Newman H; Rizel L; Khayat M; Hanna R; St Guily JL; Tiosano B; Ben-Yosef T
Genet Test Mol Biomarkers; 2017 Jul; 21(7):450-453. PubMed ID: 28590779
[TBL] [Abstract][Full Text] [Related]
33. Oculopharyngeal Muscular Dystrophy, an Often Misdiagnosed Neuromuscular Disorder: A Southern California Experience.
Goyal NA; Mozaffar T; Chui LA
J Clin Neuromuscul Dis; 2019 Dec; 21(2):61-68. PubMed ID: 31743248
[TBL] [Abstract][Full Text] [Related]
34. Animal model of oculopharyngeal muscular dystrophy.
Uyama E; Hino H; Araki K; Takeya M; Uchino M; Yamamura K
Acta Myol; 2005 Oct; 24(2):84-8. PubMed ID: 16550922
[TBL] [Abstract][Full Text] [Related]
35. Progressive myopathy in an inducible mouse model of oculopharyngeal muscular dystrophy.
Mankodi A; Wheeler TM; Shetty R; Salceies KM; Becher MW; Thornton CA
Neurobiol Dis; 2012 Jan; 45(1):539-46. PubMed ID: 21964252
[TBL] [Abstract][Full Text] [Related]
36. A Preliminary Videofluoroscopic Investigation of Swallowing Physiology and Function in Individuals with Oculopharyngeal Muscular Dystrophy (OPMD).
Waito AA; Steele CM; Peladeau-Pigeon M; Genge A; Argov Z
Dysphagia; 2018 Dec; 33(6):789-802. PubMed ID: 29725764
[TBL] [Abstract][Full Text] [Related]
37. Oculopharyngeal muscular dystrophy with limb girdle weakness as major complaint.
Van Der Sluijs BM; Hoefsloot LH; Padberg GW; Van Der Maarel SM; Van Engelen BG
J Neurol; 2003 Nov; 250(11):1307-12. PubMed ID: 14648146
[TBL] [Abstract][Full Text] [Related]
38. Two different PABPN1 expanded alleles in a Mexican population with oculopharyngeal muscular dystrophy arising from independent founder effects.
Rivera D; Mejia-Lopez H; Pompa-Mera EN; Villanueva-Mendoza C; Nava-Castañeda A; Garnica-Hayashi L; Cuevas-Covarrubias S; Zenteno JC
Br J Ophthalmol; 2008 Jul; 92(7):998-1002. PubMed ID: 18577654
[TBL] [Abstract][Full Text] [Related]
39. Cognitive impairment and reduced life span of oculopharyngeal muscular dystrophy homozygotes.
Blumen SC; Bouchard JP; Brais B; Carasso RL; Paleacu D; Drory VE; Chantal S; Blumen N; Braverman I
Neurology; 2009 Aug; 73(8):596-601. PubMed ID: 19704078
[TBL] [Abstract][Full Text] [Related]
40. The small compound Icerguastat reduces muscle defects in oculopharyngeal muscular dystrophy through the PERK pathway of the unfolded protein response.
Naït-Saïdi R; Chartier A; Abgueguen E; Guédat P; Simonelig M
Open Biol; 2023 Apr; 13(4):230008. PubMed ID: 37042114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
